This indicates that a physician should have a high index of suspicion for atezolizumab-induced aplastic anemia when faced with a patient undergoing treatment with immunotherapy presenting with new-onset hematologic abnormalities in multiple cell lines refractory to G-CSF administration. Here, CSF3 is linked to aplastic anemia.